Abstract:Objectives Paclitaxel is a potent anti-cancer drug that has exhibited clinical activity against several tumours. Unfortunately, serious side effects are associated with Taxol, the commercial formulation of paclitaxel, which contains Cremophor EL (CrEL). Currently, the main focus of developing paclitaxel formulations is on improving efficacy and reducing toxicity. A novel, Cremophor-free, paclitaxel solid dispersion (PSD) was prepared in our laboratory previously. The primary aim of this study was to evaluate the pharmacokinetics, tissue distribution, acute toxicity and anti-tumour efficacy of the PSD compared with Taxol. Methods SD rats were used to examine the pharmacokinetics and tissue distribution of PSD. The acute toxicity of PSD was evaluated in ICR mouse. The anti-tumor activity of PSD was assessed in an in vivo anti-tumor nude mice model inoculated with human SKOV-3 cancer cells. Key findings The two formulations presented different pharmacokinetic behaviour. The plasma AUC of paclitaxel in the PSD was 5.84-fold lower than that of Taxol, and the mean residence time, total body clearance and apparent volume of distribution of paclitaxel in the PSD were increased by 1.73, 4.67 and 8.57 fold, respectively. However, the two formulations showed similar tissue distribution properties. CrEL, the vehicle in Taxol, decreased the clearance of paclitaxel from plasma. The LD50 (median lethal dose) was 34.8 mg/kg for Taxol, whereas no death was observed at 160 mg/kg for the PSD. The anti-tumour activity of PSD was similar to that of Taxol at a dose of 15 mg/kg. Most importantly, the improved tolerance of PSD enabled a higher administrable dose of paclitaxel, which resulted in improved efficacy compared with Taxol administered at its maximum tolerated dose. Conclusions These results suggest that the PSD, a CrEL-free formulation, is a promising approach to increase the safety and efficacy of paclitaxel.

Characteristics, Properties and Analytical Methods of Paclitaxel: A Review

Advances in Drug Delivery Systems for Lipophilic Drug Paclitaxel: Developments, Challenges, and Opportunities (A Review)

Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and Challenges

A Study on Improving Bioavailability of Paclitaxel through different Novel Drug Delivery Approaches

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

Innovative strategies for effective paclitaxel delivery: Recent developments and prospects

Paclitaxel Drug Delivery Systems: Focus on Nanocrystals’ Surface Modifications

Progress of Clinical Research on New Nano-Drug Delivery System of Paclitaxel

An Overview of Paclitaxel and Molecular Imprinted Polymers Capped with Quantum Dots as an Alternative Approach for Paclitaxel Extraction and Detection

Research Advances in Clinical Applications, Anticancer Mechanism, Total Chemical Synthesis, Semi-Synthesis and Biosynthesis of Paclitaxel

Research progress of paclitaxel drug delivery systems

Progress on the Prodrugs of Paclitaxel

Exploration and Outlook of Recent Applications of Paclitaxel in Breast Cancer Treatment

Preparation and Characterization of Paclitaxel Delivery System Based on Semi-Solid Lipid Nanoparticles Coated with Poly (ethylene Glycol).

Progress of clinical research and new formulations of paclitaxel

Strategies in Taxol development. A review.

Preparation and in Vitro Evaluation of Paclitaxel-Loaded Poly(lactide-co-glycolide) Nanoparticles

Preparation and Targeted Release Evaluation Studies on Micro-Encapsulation of Paclitaxel

Solubilization Methods for Paclitaxel and Docetaxel: An Overview